In cardiovascular and metabolic diseases, isoform-specific targeting of ROCK1 or ROCK2 holds promise for improving endothelial function, attenuating fibrosis, and protecting against diabetic complications such as cardiomyopathy and nephropathy. Here, ROCK2 is linked to metabolic disease.